Welcome

This comprehensive review from JAMA outlines the most up-to-date diagnostic and treatment strategies for infertility, emphasizing that 85% of infertility cases have an identifiable cause—most commonly ovulatory dysfunction, male factor infertility, or tubal disease. The paper reinforces the value of tailored treatment: ovulation induction with letrozole (preferred for PCOS) or clomiphene for anovulation; surgical or IVF options for tubal blockages; and ovarian stimulation plus intrauterine insemination (IUI) or direct IVF for unexplained infertility.

This study highlights that medical treatments like hormonal suppression relieve pain but do not improve pregnancy rates, especially in moderate to severe endometriosis. Surgical removal of visible lesions can improve fertility in mild cases, while IVF is the most effective option for advanced stages—particularly when combined with surgery. In one analysis, surgery followed by IVF led to a 56% pregnancy rate, compared to 37% with surgery alone, emphasizing the importance of a personalized, integrated treatment plan.

This review reveals that immune-related infertility—especially from anti-sperm and anti-seminal fluid antibodies—is more common than previously recognized and can interfere with every stage of fertilization. While certain antibodies may be harmless, others can block sperm motility, binding, and implantation. The authors suggest that early identification of specific antibody types (especially IgG1 and IgG4) could guide immunotherapies and improve treatment for women with unexplained infertility linked to immune dysfunction.

This review shows that sperm antibodies (SpAbs) can impair fertility by disrupting sperm motility, mucus penetration, and egg interaction, often following trauma, infection, or obstruction. While testing remains limited, intracytoplasmic sperm injection (ICSI) has become the most effective treatment—successfully bypassing the effects of SpAbs and leading to normal fertilization and pregnancy outcomes even in severe cases.

This landmark review reveals that hundreds of newly discovered genes influence fertility across every stage—from hormone signaling to egg and sperm development. Though assisted reproductive technologies (ART) have helped many, the authors stress that true progress lies in translating these genetic insights into better diagnostics and treatments. Promising areas include stem cell-based regenerative therapies, gene-targeted interventions, and deeper investigation of immune and endocrine factors in unexplained infertility.

This Lancet review highlights that male infertility is often linked to treatable medical, hormonal, or lifestyle factors, and that advanced diagnostics like sperm DNA fragmentation and oxidative stress testing can help tailor care. Treatments such as varicocele repair, hormone therapy, and antioxidant supplements show promise, while ICSI and testicular sperm retrieval offer paths to parenthood even in severe cases. Future therapies like stem cell and gene-based treatments are on the horizon, showing potential for regenerative fertility care.

Awards fertility treatment grants (including IVF, egg donation, and surrogacy) to individuals and couples across the U.S.

Offers grants up to $10,000 for fertility treatment or adoption to families struggling with infertility.

Provides quarterly grants to help cover IVF, egg/sperm donation, gestational surrogacy, and embryo adoption.
 

Offers tools and guidance to help patients advocate for insurance coverage and access fertility benefits.

Hosts 5K races and raffles where participants can win grants toward fertility treatments.

Provides grants to cover treatment costs for medically diagnosed infertility cases.